#USA #Marietta #Airway Therapeutics #Zelpultide Alfa #Joe Todisco

Airway Therapeutics' New Direction with Joe Todisco on Board

In a strategic move aimed at strengthening its leadership, Airway Therapeutics, a company specialized in developing cutting-edge biologic therapies for respiratory and inflammatory diseases, has appointed Joe Todisco to its Board of Directors effective April 13, 2026. With over two decades of experience in the pharmaceutical and biotechnology realms, Todisco's appointment is set to boost the company's initiatives towards advancing its lead candidate, zelpultide alfa.

A Strong Addition to the Team

Joe Todisco is not new to the biopharmaceutical scene; he is the Chairman and CEO of CorMedix Inc. and has played an integral role in shaping commercial strategies within various companies. His invitation to join the board of Airway Therapeutics underscores the company's commitment to achieving its strategic vision and navigating through late-stage development of its products.

Marc Salzberg, MD, who serves as both Chairman and CEO at Airway Therapeutics, emphasized the importance of Todisco’s extensive knowledge in commercial operations. He remarked, "Joe's rich experience in scaling specialty pharmaceuticals will be invaluable as we propel zelpultide alfa towards commercialization. His insight is expected to significantly impact our approach within the hospital channel, which is crucial for the upcoming launch of our lead product aimed at treating bronchopulmonary dysplasia (BPD)."

Addressing Unmet Medical Needs

BPD is a critical condition affecting very preterm infants, with no approved preventive therapies available. Airway Therapeutics is at the forefront of addressing this unmet medical need with zelpultide alfa, a biologic product currently undergoing late-stage clinical trials. The hopes are high, not just for this particular candidate but for the potential expansion of its applications in treating various diseases across different age demographics.

As Todisco prepares to join the board, he expresses enthusiasm about contributing to Airway’s bold initiatives. "This is an important time for the company, and I look forward to joining Airway's Board of Directors to help advance its pipeline and strategic vision," he stated, highlighting the innovative approach the company is adopting in biologic therapies.

Todisco’s Background and Experience

Before joining CorMedix, Todisco accumulated substantial expertise at Amneal Pharmaceuticals, where he served in senior leadership roles for eleven years, including positions such as Chief Commercial Officer and Senior VP of Corporate Development. He also co-founded Gemini Laboratories LLC, which was later acquired by Amneal, further showcasing his entrepreneurial skills and strategic mindset.

Educationally, Todisco holds a bachelor’s degree in Economics from Georgetown University and an MBA from Fordham Graduate School of Business, grounding his extensive corporate journey in robust academic knowledge. His prior roles include leading North American commercial strategy at Ranbaxy Pharmaceuticals and various leadership responsibilities at Par Pharmaceuticals.

Looking Ahead

Airway Therapeutics is embedding strategic leadership with Todisco's addition, seeking not only to further its pipeline but also to refine its overall strategic direction. As they usher in this new chapter, the company remains focused on improving outcomes for patients and addressing critical public health challenges.

For further details on Airway Therapeutics and their innovative therapies, visit their official website at airwaytherapeutics.com.